Results 11 to 20 of about 82,153 (256)

Beating the odds: Successful establishment of a Phase II/III clinical research trial in resource-poor Liberia during the largest-ever Ebola outbreak

Contemporary Clinical Trials Communications, 2016
It has been argued that a country such as Liberia, not fully recovered from the devastation of decades of civil unrest, lacked the appropriate ethical and regulatory framework, basic human and health care services, and infrastructure to carry out ...
J. Doe-Anderson, B. Baseler, P. Driscoll, M. Johnson, J. Lysander, L. McNay, W.S. Njoh, M. Smolskis, L. Wehrlen, J. Zuckerman   +9 more
doaj   +2 more sources

Final Rule: HHS and NIH’s New Information Requirements for Clinical Trials

Voices in Bioethics, 2016
On September 16, 2016, the U.S. Department of Health and Human Services (HHS) presented a final rule, in conjunction with a complementary policy of the National Institutes of Health (NIH), amending Tile 42, Chapter 1 of the Code of Federal Regulations[1].
Jorge Luis Rivera-Agosto
doaj   +2 more sources

Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience

Therapeutic Advances in Neurological Disorders, 2017
Key objectives in the treatment of multiple sclerosis (MS) include prevention of relapses, a reduction in the accumulation of disability and slowing of the brain volume loss that occurs from the earliest stages of the disease. Teriflunomide, a once-daily,
Aaron E. Miller
doaj   +3 more sources

High-dose vitamin C as a targeted treatment for KRAS-driven cancers?

Redox Biology
KRAS mutations are frequently observed in human cancer and are associated with proliferation, therapy-resistance and worse outcome. Regrettably, only a fraction of possible mutations is druggable.
Elisabeth Mack, Christian Rau, Cornelia Otet, Jonas Aaron Schäfer, Cornelia Brendel, Albert Grass, Peer Bredow, Christian Hohl, Carsten Denkert, Frank Willeke, Andreas Neubauer   +10 more
doaj   +2 more sources

Maintenance chemotherapy in advanced and metastatic pancreatic cancer, a narrative review and case series [PDF]

, 2023
Limited data exist on the management of patients with locally advanced (aPC) or metastatic pancreatic (mPC) cancer who achieve stable disease/response after first-line chemotherapy.
Monita Al Darazi, Ziad Salem, Deborah Mukherji, Mukherji, Deborah M., Shamseddine, Ali I., Laudy Chehade, Charafeddine, Maya A., Sally Temraz, Charbel Elias, Ali Shamseddine, Chehade, Laudy, Elias, Charbel M., Temraz, Sally N., Darazi, Monita Al, Maya Charafeddine, Salem, Ziad M.   +15 more
core   +1 more source

Post-COVID condition or “long COVID”, return-to work, and occupational health research

Scandinavian Journal of Work, Environment & Health, 2023
Since the beginning of the COVID-19 pandemic, there has been a growing literature on COVID and work (1). Major editorials (2–4) and reports from international associations and agencies (5–8) have highlighted the importance of ...
Alexis Descatha, Bradley A Evanoff, Marc Fadel   +2 more
doaj   +1 more source

Current evidence linking polyunsaturated fatty acids (PUFAs) with cancer risk and progression

Frontiers in Oncology, 2013
There is increasing evidence that polyunsaturated fatty acids (PUFAs) play a role in cancer risk and progression. The n-3 family of PUFAs includes alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) while the n-6 family
Maria eAzrad, Chelsea Elizabeth Turgeon, Wendy eDemark-Wahnefried   +2 more
doaj   +1 more source

New drugs against trypanosomatid parasites : rediscovery of fexinidazole [PDF]

, 2014
Neglected tropical diseases (NTDs) are a group of communicable diseases mostly affecting people in developing countries. These diseases are responsible for a major part of the global morbidity, mortality and poverty. There is no doubt that the well-being
Kaiser, Marcel
core   +1 more source

Clinical Outcome of Topical Interferon Alpha-2b Cream in Phase II Trial for LSIL/CIN 1 Patients

Journal of Cancer Therapy, 2011
Objectives: Interferon alpha-2b possesses variable activity against human papillomavirus (HPV) associated cervical intraepithelial neoplasia (CIN). No topical therapy is currently available for treatment of early stage CIN. We evaluated a new patented drug delivery technology in order to achieve topical efficacy.
Roberto Kurzeja, Gerd Böhmer, Achim Schneider   +2 more
openaire   +2 more sources

Phase II AIDS Malignancy Consortium (AMC) trial of topical halofuginone in AIDS-associated Kaposi’s sarcoma (KS): clinical and biological effects using a novel intra-patient control design [PDF]

Infectious Agents and Cancer, 2010
Background KS is a disease of multifocal vascular proliferation. Matrix metalloproteinases (MMPs) and type I collagen play critical roles in angiogenesis and are potential targets. Halofuginone (Tempostatin™), a synthetic quinazolinone alkaloid derivative, induced anti-angiogenic, anti-metastatic and anti-proliferative effects in preclinical studies ...
Krown, Susan E, Fingleton, Barbara, Lee, Jeannette Y, Egorin, Merrill J, Koon, Henry B   +4 more
openaire   +2 more sources